Literature DB >> 33523357

The yield of CSF molecular testing in febrile neonates.

Basheer Nassrallah1, Ellen Bamberger1,2, Sarah Cohen3, Isaac Srugo1,2,4, Orit Golan-Shany4, Yulia Shlonsky4, Raeda Mubariki4, Jacob Genizi5,6,7.   

Abstract

We retrospectively examined the yield of a cerebrospinal fluid (CSF) multiplex real-time PCR assay of febrile young infants undergoing a full sepsis work-up. Eighty infants were included in the study: Forty-nine (61%) neonates and 31 (39%) 29-90 day-old patients were included in the study. A viral pathogen was detected in 59% (47/80) of the samples, human enterovirus in 53% (42/80) and Human parechovirus in 6% (5/80). The CSF of nearly half of the subjects with CNS infection was without pleocytosis; all CSF cultures were negative. Multiplex PCR CSF testing enhances the diagnosis of pathogen-specific viral CNS infection among febrile young infants.

Entities:  

Keywords:  Infants; Infection; Meningitis; Multiplex PCR

Year:  2021        PMID: 33523357     DOI: 10.1007/s10096-021-04168-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Reference values of normal cerebrospinal fluid composition in infants ages 0 to 8 weeks.

Authors:  W A Bonadio; L Stanco; R Bruce; D Barry; D Smith
Journal:  Pediatr Infect Dis J       Date:  1992-07       Impact factor: 2.129

2.  Prevalence and predictors of bacterial meningitis in young infants with fever without a source.

Authors:  Elena Martinez; Santiago Mintegi; Begoña Vilar; Maria Jesus Martinez; Amaia Lopez; Estibaliz Catediano; Borja Gomez
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

3.  Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management.

Authors:  C Ramers; G Billman; M Hartin; S Ho; M H Sawyer
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

4.  Unpredictability of serious bacterial illness in febrile infants from birth to 1 month of age.

Authors:  M D Baker; L M Bell
Journal:  Arch Pediatr Adolesc Med       Date:  1999-05

5.  Meta-analysis to Determine Risk for Serious Bacterial Infection in Febrile Outpatient Neonates With RSV Infection.

Authors:  William Bonadio; Felix Huang; Sinthumathi Nateson; Chukwujekwu Okpalaji; Alicia Kodsi; Sabrina Sokolovsky; Peter Homel
Journal:  Pediatr Emerg Care       Date:  2016-05       Impact factor: 1.454

6.  Lack of cerebrospinal fluid pleocytosis in young infants with enterovirus infections of the central nervous system.

Authors:  Jeffrey A Seiden; Joseph J Zorc; Richard L Hodinka; Samir S Shah
Journal:  Pediatr Emerg Care       Date:  2010-02       Impact factor: 1.454

7.  Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections.

Authors:  Carrie L Byington; F Rene Enriquez; Charles Hoff; Richard Tuohy; E William Taggart; David R Hillyard; Karen C Carroll; John C Christenson
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

8.  Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research.

Authors:  L J Baraff; J W Bass; G R Fleisher; J O Klein; G H McCracken; K R Powell; D L Schriger
Journal:  Ann Emerg Med       Date:  1993-07       Impact factor: 5.721

9.  Outcome of routine cerebrospinal fluid screening for enterovirus and human parechovirus infection among infants with sepsis-like illness or meningitis in Cornwall, UK.

Authors:  Prithwiraj Chakrabarti; Chris Warren; Laura Vincent; Yadlapalli Kumar
Journal:  Eur J Pediatr       Date:  2018-07-18       Impact factor: 3.860

10.  Retrospective Evaluation of Infants Aged 1 to 60 Days with Residual Cerebrospinal Fluid (CSF) Tested Using the FilmArray Meningitis/Encephalitis (ME) Panel.

Authors:  Anne J Blaschke; Kristen M Holmberg; Judy A Daly; Amy L Leber; Jennifer Dien Bard; Ernest K Korgenski; Kevin M Bourzac; Kristen J Kanack
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.